Gilead tack­les a big PhI­II pro­gram for block­buster hope­ful fil­go­tinib

Gilead $GILD has em­barked on an am­bi­tious Phase III pro­gram for fil­go­tinib, one of the most close­ly-watched drugs now in the late-stage pipeline for rheuma­toid arthri­tis.

The sto­ried Gala­pa­gos drug, which had been dumped by Ab­b­Vie on­ly to be quick­ly picked back up in a rich deal with Gilead, is be­ing put through three late-stage stud­ies – dubbed FINCH 1, 2 and 3 – which will test two dos­es in more than 3,000 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER